RGNXHIGH SIGNALFINANCIAL10-K

RGNX shows deteriorating financial position with total liabilities increasing 69.8% to $350.3M while stockholders' equity fell 60.4% to $102.7M, indicating significant balance sheet stress.

The dramatic increase in liabilities coupled with the substantial decline in stockholders' equity suggests potential financial distress or major restructuring activity that materially weakens the company's capital position. The reduction in cash reserves to $34.5M further compounds concerns about the company's ability to fund operations, particularly given the continued substantial operating losses.

Comparing 2026-03-05 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

RGNX's financial position deteriorated meaningfully during the period, with total liabilities growing substantially to $350.3M while stockholders' equity contracted significantly to $102.7M. While operating losses improved modestly and interest expense declined notably to $6.9M, the company continues burning cash at elevated levels with operating cash flow remaining deeply negative at -$124.0M. The combination of reduced cash reserves, expanded liabilities, and ongoing substantial losses signals heightened financial stress for this gene therapy development company.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-70.5%
$23.3M→$6.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
+69.8%
$206.3M→$350.3M

Liabilities grew 69.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-60.4%
$259.7M→$102.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-40.1%
$57.5M→$34.5M

Cash declined 40.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+30.9%
-$233.3M→-$161.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
+28.8%
$20.5M→$26.4M

Receivables grew 28.8% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
+28.4%
-$173.1M→-$124.0M

Operating cash flow grew 28.4% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+14.6%
-$227.1M→-$193.9M

Net income grew 14.6% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+14.4%
$103.2M→$118.1M

Current liabilities rose 14.4% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-13
ADDED
As of February 27, 2026, there were 51,612,984 shares of the registrant s common stock, par value $0.0001 per share, issued and outstanding.
However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, uncertainties, assumptions and other important factors, including, but not limited to: our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize surabgene lomparvovec (sura-vec, ABBV-RGX-314) and our collaboration with Nippon Shinyaku Co., Ltd.
Our investigational gene therapies include: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Since our inception, we have built and advanced multiple promising gene therapies into late-stage clinical development.
All of our gene therapies were built on our NAV Technology Platform.
Together, with our in-house, U.S.-based manufacturing and end-to-end capabilities, we are excited about the prospect of bringing these assets to commercial stage and continuing to leverage our NAV Technology Platform to generate additional promising gene therapies.
Our NAV Technology Platform has enabled the development of a number of gene therapies being investigated in clinical trials and two that are FDA-approved.
These partnered programs include Novartis Zolgensma and Itvisma gene therapies for the treatment of spinal muscular atrophy (SMA), a debilitating and potentially deadly disease.
Food and Drug Administration (FDA) in 2019 for the treatment of SMA in patients under the age of two years old, and Itvisma was approved by the FDA in November 2025 for the treatment of SMA in patients two years and older.
Together, Zolgensma and Itvisma have been used to treat thousands of patients suffering from SMA.
REMOVED
As of March 7, 2025, there were 50,086,138 shares of the registrant s common stock, par value $0.0001 per share, issued and outstanding.
We refer to commercial and investigational AAV vector-based gene therapies as AAV Therapeutics.
Our investigational AAV Therapeutics include: ABBV-RGX-314, which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision.
RGX-202, which we are developing to treat Duchenne muscular dystrophy (Duchenne), one of the most common fatal genetic disorders affecting children.
Since our inception, we have built and advanced multiple promising AAV Therapeutics into late-stage clinical development.
All of our AAV Therapeutics were built on our NAV Technology Platform.
Together, with our manufacturing and end-to-end capabilities, we are excited about the prospect of bringing these assets to commercial stage and continuing to leverage our NAV Technology Platform to generate additional promising AAV Therapeutics.
Our NAV Technology Platform has enabled the development of a number of AAV Therapeutics being investigated in clinical trials and one that is FDA-approved.
For many years, by sublicensing NAV Vectors from our NAV Technology Platform to other biopharmaceutical companies with disease-specific expertise, which we refer to as our NAV Technology Licensees, we received capital to advance our own research and capabilities.
These partnered programs include Novartis Zolgensma , a gene therapy for the treatment of spinal muscular atrophy (SMA), which was approved by the U.S.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →